During the COVID-19 pandemic, pipette tips became an unexpected symbol of supply-chain fragility.

The shortage was easy to underestimate. A pipette tip is small, inexpensive, and normally treated as an endlessly available disposable. Yet without the correct tips, many automated instruments cannot operate. Sample preparation stops. Testing slows. Research timelines slip. An inexpensive consumable can become the constraint on an entire laboratory.

The events of 2020 and 2021 showed how quickly that can happen. Current pressure on global energy, petrochemical, and shipping markets does not guarantee another shortage, but some of the warning signs look familiar.

What caused the COVID-era pipette tip shortage?

There was no single cause. Several disruptions arrived at once and amplified one another.

First, COVID-19 testing created an enormous increase in demand. Each PCR workflow required multiple liquid transfers, with a new tip used to prevent cross-contamination. With millions of tests being performed every day, manufacturers were asked to supply far more tips than their production systems had been designed to produce.

At the same time, demand for other laboratory plastics, medical devices, packaging, and personal protective equipment was climbing. Many of these products depended on the same raw materials and manufacturing capacity.

Then supply itself was disrupted. Winter Storm Uri caused widespread power outages in Texas in February 2021, temporarily shutting down facilities that produced polypropylene resin, the primary material used to manufacture most pipette tips. Fires, transportation delays, labor shortages, and other interruptions added pressure at different points in the supply chain. Smithsonian Magazine’s reporting at the time described how pandemic demand and severe weather combined to disrupt production of basic laboratory plastics.

Increasing supply was not as simple as running existing machines faster. Pipette tips require precision molds, specialized production equipment, controlled manufacturing environments, and, for filtered tips, additional components and assembly capabilities. A U.S. International Trade Commission report found that new molds could take 16 to 20 weeks to source, while a new automated production line could take 8 to 14 months to establish. Filter availability created an additional bottleneck.

Even when tips were technically available, they were not always interchangeable. Labs often needed specific tip geometries, filters, purity levels, conductivity, or compatibility with a particular liquid handler. A shipment of the wrong tips could not keep a validated workflow running.

The effect reached far beyond COVID testing

The shortage did not remain confined to diagnostic laboratories.

Research labs delayed experiments and spent more time monitoring inventory. Drug-development teams considered which programs should receive their remaining supplies. Some laboratories extended ordering timelines, rationed tips, borrowed inventory from other facilities, or attempted improvised cleaning methods.

The consequences were especially serious for public-health programs. In early 2021, laboratories in 14 states reportedly had less than one month of pipette-tip inventory available. Some newborn-screening laboratories began processing samples in batches or seeking emergency supplies from other states, creating concern about delays in time-sensitive testing. STAT documented how the shortage affected newborn screening, university research, and pharmaceutical development.

The larger lesson was that a lab does not need to run out completely for a shortage to cause damage. Long and unreliable lead times can create their own operational burden:

• Procurement teams spend more time locating acceptable inventory.
• Labs carry larger safety stocks and commit more cash to consumables.
• Researchers adjust schedules around supply availability.
• Validated workflows may require new compatibility testing.
• High-throughput instruments risk sitting idle while inexpensive plastic is unavailable.

The true cost was not simply a higher price per rack. It was lost predictability.

Why current events deserve attention

As of July 2026, conflict in the Middle East is once again disrupting energy, petrochemical, and shipping markets.

Polypropylene begins upstream in the petrochemical supply chain. Its availability and price can be affected by crude oil and natural-gas markets, refinery and chemical-plant operations, international shipping routes, freight costs, insurance costs, and competition for manufacturing capacity.

The Strait of Hormuz is particularly important to this system. Large volumes of oil, feedstocks, petrochemicals, and finished polymers normally move through the region. Disruption does not have to remove all material from the market to have an effect. Delays and uncertainty can force manufacturers to locate replacement supplies, pay more for transportation, or compete for material from other producers.

In March, Reuters reported that Middle East disruptions had pushed polyethylene and polypropylene prices to roughly four-year highs. Polypropylene prices on China’s Dalian Commodity Exchange had risen more than 38 percent since the conflict began. By late July, Saudi chemical producer SABIC reported that war-related disruptions had hampered shipments, while its sales volumes fell and average selling prices increased. The company also had to reroute more polymer shipments through western Saudi Arabia.

None of this means laboratories will necessarily experience a repeat of 2021. North American resin production is relatively well positioned, suppliers may hold inventory, and market conditions are different from those of the pandemic. A higher polypropylene price also does not automatically translate into an immediate shortage of finished pipette tips.

It does, however, reveal the same underlying exposure: labs remain dependent on a long, specialized supply chain for a consumable they use once and cannot operate without.

Resilience requires more than a larger stockroom

The traditional response to supply uncertainty is to purchase more inventory. That can provide temporary protection, but it also ties up cash, requires storage space, and may intensify demand when many organizations begin stockpiling simultaneously.

Diversifying suppliers can help, although liquid-handler compatibility, validated protocols, filter requirements, and quality specifications often limit the number of viable alternatives.

A more structural approach is to reduce the number of new tips the laboratory must purchase in the first place.

Validated pipette-tip reuse gives laboratories an internal source of usable inventory. Instead of relying entirely on the next shipment, a portion of the tips already inside the facility can be cleaned and returned to service. This does not require a lab to predict whether the next disruption will come from a pandemic, extreme weather, a factory shutdown, or a geopolitical conflict.

At sufficient scale, reuse changes the role of the pipette tip. It becomes less like a disposable item that must constantly be replaced and more like operational inventory that circulates through the laboratory.

IonField Systems’ PureTIP One uses room-temperature plasma to decontaminate racks of pipette tips for immediate reuse. It can process up to 70 racks per hour and is designed to clean standard, filtered, and conductive tips. Because the process does not leave tips wet, there is no drying stage before they return to the workflow.

The immediate benefit is a reduction in disposable-tip purchasing and plastic waste. The broader benefit is resilience. Every rack safely returned to service is one less rack that must be available from a supplier at exactly the right time.

The warning is not the same as the outcome

The COVID-era shortage was not caused by one failed factory or one unavailable material. It emerged when extraordinary demand met a supply chain with limited flexibility and long expansion timelines.

Today’s conditions are different, but the warning is similar. Polypropylene markets are under pressure. Shipping routes are uncertain. Petrochemical producers are rerouting material and raising prices. Labs still depend on highly specific disposable products that cannot always be replaced quickly.

Another pipette-tip shortage is not inevitable. That is precisely why this is the right time to prepare. Resilience is most effective when it is built before allocation notices arrive, lead times expand, and every laboratory begins searching for the same limited inventory.